AstraZeneca (LON:AZN) Earns Overweight Rating from JPMorgan Chase & Co.

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reiterated by research analysts at JPMorgan Chase & Co. in a report issued on Thursday, April 4th, MarketBeat Ratings reports.

Other equities research analysts have also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of AstraZeneca in a research report on Tuesday, March 12th. UBS Group lowered their price objective on shares of AstraZeneca from £107 ($133.20) to GBX 9,900 ($123.24) and set a “sell” rating for the company in a research report on Monday, February 12th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research report on Thursday, February 8th. BMO Capital Markets reiterated an “outperform” rating on shares of AstraZeneca in a research report on Monday, February 12th. Finally, Berenberg Bank reiterated a “buy” rating on shares of AstraZeneca in a research report on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of £115.43 ($143.69).

AstraZeneca Trading Up 0.2 %

AZN opened at £108.86 ($135.52) on Thursday. The company has a current ratio of 0.82, a quick ratio of 0.59 and a debt-to-equity ratio of 75.70. The stock has a market capitalization of £168.73 billion, a PE ratio of 3,584.82, a PEG ratio of 0.89 and a beta of 0.19. AstraZeneca has a 1-year low of GBX 9,461 ($117.78) and a 1-year high of £123.48 ($153.72). The firm has a 50-day moving average price of £103.49 and a two-hundred day moving average price of £104.25.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.